HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Sulphasalazine in ankylosing spondylitis.

Abstract
In recent years sulphasalazine has gained acceptance as an effective agent for the treatment of rheumatoid arthritis. Ankylosing spondylitis is a disease where remission inducing drugs so far have been lacking. In this double blind trial sulphasalazine was compared with placebo in 37 patients with ankylosing spondylitis. Evaluation after three months' treatment showed reduction of inflammatory activity and improvement of clinical variables. The side effects were mild. The results suggest that sulphasalazine is a potentially effective and safe drug in the treatment of ankylosing spondylitis.
AuthorsN Feltelius, R Hällgren
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 45 Issue 5 Pg. 396-9 (May 1986) ISSN: 0003-4967 [Print] ENGLAND
PMID2872857 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
Chemical References
  • Haptoglobins
  • Orosomucoid
  • Sulfasalazine
Topics
  • Adult
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Haptoglobins (analysis)
  • Humans
  • Male
  • Middle Aged
  • Orosomucoid (analysis)
  • Spondylitis, Ankylosing (blood, drug therapy)
  • Sulfasalazine (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD